8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
Baxter raises 2026 outlook after second-quarter sales rise 5%
Filed with the SEC on · Summarized by InvestorsBot
Baxter reported second-quarter 2026 sales of $2.96 billion for the period ended June 30, up 5% on both a reported and organic basis, with U.S. GAAP diluted EPS of $0.26 and adjusted diluted EPS of $0.56. On July 30, 2026, the company raised its full-year outlook to reported sales growth of 3% to 4%, organic sales growth of 2% to 3%, and adjusted diluted EPS of $1.95 to $2.15, citing operating performance and a $0.11-per-share benefit from an IEEPA tariff refund.